Akèy › Maladi poumon entèstisyèl › Texas › Dallas
Etid klinik pou Maladi poumon entèstisyèl nan Dallas, TX
9 etid pou Maladi poumon entèstisyèl ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Ap rekriteFaz 3
- Baylor University Medical Center, Dallas
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Ap rekriteFaz 2
- Baylor University Medical Center, Dallas
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Ap rekrite
- Baylor University Medical Center, Dallas
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Ap rekriteEtid obsèvasyon
- Baylor University Medical Center, Dallas
- UT Southwest Medical Center Heart and Lung Clinic, Dallas
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern, Dallas
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern, Dallas
- Baylor University Medical Center at Dallas, Dallas
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Ap rekriteFaz 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center-Advanced Lung Clinic, Dallas
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Ap rekriteFaz 2
- University of Texas Southwestern Medical Center, Dallas
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Ap rekriteFaz 2
- aTyr Investigative Site, Dallas
Etid Maladi poumon entèstisyèl nan lòt vil
- New York City, NY18 etid
- Philadelphia, PA16 etid
- Los Angeles, CA14 etid
- Kansas City, KS13 etid
- Durham, NC13 etid
- Charleston, SC13 etid
- Chicago, IL12 etid
- Houston, TX12 etid
- Ann Arbor, MI11 etid
- Aurora, CO11 etid
- Phoenix, AZ9 etid
- Salt Lake City, UT9 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè vejik27 etid
- Kansè poumon27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.